Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 5/20 | 0.38 |
| ▸ | DUT | P33316 | 2/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.35 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.35 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.35 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.34 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18057128 | 0.85 | P2RY14 (0.47) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL18057137 | 0.84 | P2RY14 (0.42) | P2RY6P2RY14P2RY2P2RY4 | |
| SCHEMBL22060534 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL15280854 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL19887045 | 0.83 | ALDH1A1 (0.38) | — | |
| SCHEMBL18058970 | 0.79 | P2RY6 (0.41) | P2RY6P2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14702142 | 0.79 | P2RY6 (0.41) | P2RY6P2RY14SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12408858 | 0.79 | DUT (0.43) | P2RY6DUTP2RY14SLC28A1SLC28A2 | |
| SCHEMBL12191314 | 0.79 | DUT (0.43) | P2RY6DUTP2RY14SLC28A1SLC28A2 | |
| SCHEMBL12408866 | 0.79 | DUT (0.43) | P2RY6DUTP2RY14SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9803199-B2 | Cationic lipid | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20160257951-A1 | NOVEL LIPID | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257951-A1 | NOVEL LIPID | NPC1L1, CETP, LIPC | P2RY6 1969/4885DUT 1248/4885P2RY14 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.